CytomX Snags $25M From Pfizer to Make Souped-Up Antibodies
Pfizer was tripped up a couple years ago, when safety concerns emerged around the first drug ever approved that could combine the targeting ability of an antibody with a toxin to give it more tumor-killing kick. But the New York-based pharma giant ...
CytomX Announces Global Strategic Collaboration with Pfizer to Develop and (press release)
Pfizer, CytomX in Up To $635M Cancer CollaborationGenetic Engineering News
Pfizer Keeping the ADC Faith: Potential $635M CytomX DealBioWorld Online

all 5 news articles »